- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT01021397
Safety of and Immune Response to Recombinant Live Attenuated Parainfluenza Type 3 Virus Vaccine in Healthy Infants and Children
Phase I Study to Determine the Safety, Infectivity, and Tolerability of 2 Doses of Live Attenuated Recombinant Cold-Passaged (cp) 45 Human Parainfluenza Type 3 Virus Vaccine, rHPIV3cp45, Lot PIV3#102A, Delivered as Nose Drops to HPIV3-Seronegative Infants and Children 6 to 36 Months of Age, at a 6 Month Interval
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
HPIV type 3 (HPIV3) ranks second only to respiratory syncytial virus as the most important cause of bronchiolitis and pneumonia in infants less than 6 months of age. HPIV3 can cause severe disease in the first 2 years of life and is responsible for 11% of hospitalizations for respiratory diseases in children. This study will evaluate the safety and immunogenicity of a live recombinant attenuated intranasal HPIV3 vaccine, rHPIV3cp45.
This study will last for approximately 28 weeks. Infants and children 6 months to 36 months of age will be randomly assigned to one of two groups. Group 1 participants will receive 2 immunizations of rHPIV3cp45. Group 2 participants will receive 2 doses of rHPIV3cp45 placebo. Immunizations will be given as nose drops and administered at study entry and approximately 22 to 27 weeks after study entry.
On the day of immunization, a physical exam and blood collection will occur. Participants will be observed for 15 minutes after immunization for any immediate adverse effects. Parents or guardians will be given a thermometer to take with them and will be instructed on how to take their child's temperature. They will be given the study schedule and will need to provide contact phone numbers so study personnel can contact them by phone during the days after immunization. Parents and guardians will be contacted by telephone daily from Day 1 to Day 18 after each immunization.
Parents or guardians will need to record their child's temperature daily for at least 17 days immediately following immunization. During this 17-day period, study visits will occur on Days 3, 6, and 12 after each dose of vaccine or placebo. Participants will undergo a nasal wash for a viral culture at all study visits. There will be additional follow-up visits occurring sometime between 49 and 63 days after the first dose and 28 to 35 days after the second dose; blood collection will occur at the follow-up visits. Additional visits may be required on selected days during the month after immunization. Infants who experience illness or side effects may be asked to return to the clinic for examination.
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 1
Contacten en locaties
Studie Locaties
-
-
Maryland
-
Baltimore, Maryland, Verenigde Staten, 21205
- Center for Immunization Research (CIR), Johns Hopkins School of Public Health
-
-
Washington
-
Seattle, Washington, Verenigde Staten, 98105
- Seattle Children's Hospital
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Good general health
- HPIV3-uninfected
- Has received age-appropriate inactivated or subunit routine immunizations at least 2 weeks prior to study entry
- Has received age-appropriate live routine immunizations at least 4 weeks prior to study entry and at least 2 weeks for rotavirus and inactivated vaccines
- Available for the duration of the trial
- Parent or guardian reachable by telephone for post-immunization contact
- Parent or guardian willing to provide informed consent
Exclusion Criteria:
- Known or suspected impairment of immunologic functions. Infants who are HIV-infected, who are bone marrow or solid organ transplant recipients, or who have received immunosuppressive therapy, including systemic corticosteroids within 30 days prior to study entry. Infants who are using topical steroids, topical antibiotic ointments and topical antifungal agents are not excluded.
- Major congenital malformations, including congenital cleft palate, cytogenetic abnormalities, or serious chronic disorders
- Previously received HPIV3 vaccine
- Previous serious vaccine-associated adverse event or anaphylactic reaction
- Known hypersensitivity to any vaccine component
- Lung or heart disease, including reactive airway disease. Infants with clinically insignificant cardiac abnormalities are not excluded. Infants or children who wheezed once or received bronchodilator therapy once in the first year of life but who have not had any additional wheezing episodes or bronchodilator therapy for at least 12 months are not excluded.
- Born prematurely before the 37th week of pregnancy if participant is currently less than 12 months of age
- Member of a household containing immunocompromised individuals, pregnant caregivers, or infants less than 6 months of age
- Attends day care with infants less than 6 months of age
- Parent or guardian unable or unwilling to suspend daycare for 14 days following each immunization. More information on this criterion can be found in the protocol.
- Enrolled in another investigational drug or vaccine study from 30 days prior to study entry until the final follow-up blood draw
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Preventie
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Verdrievoudigen
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Experimenteel: 1
Participants will receive one dose of vaccine virus at study entry and between Weeks 22 and 27
|
10^5 TCID50 nasal drops
|
Placebo-vergelijker: 2
Participants will receive one dose of vaccine virus placebo at study entry and between Weeks 22 and 27
|
1X-L15 nasal drops
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
---|---|
Frequentie van vaccingerelateerde reactogeniciteitsgebeurtenissen en andere bijwerkingen
Tijdsspanne: Gedurende de hele studie
|
Gedurende de hele studie
|
Amount of serum antibody induced by vaccine in each recipient
Tijdsspanne: Throughout study
|
Throughout study
|
Secundaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
---|---|
Fenotypische stabiliteit van de verspreiding van het vaccinvirus
Tijdsspanne: Gedurende de hele studie
|
Gedurende de hele studie
|
Amount of vaccine virus shed by each recipient
Tijdsspanne: Throughout study
|
Throughout study
|
Immunogenicity of a second dose of vaccine and the protection of the first dose against re-infection with the second dose
Tijdsspanne: From Weeks 22 to 28
|
From Weeks 22 to 28
|
Number of vaccinated infants infected with rHPIV3cp45
Tijdsspanne: Throughout study
|
Throughout study
|
Number of vaccinated participants infected with a second dose of rHPIV3cp45
Tijdsspanne: From Weeks 22 to 28
|
From Weeks 22 to 28
|
Medewerkers en onderzoekers
Medewerkers
Onderzoekers
- Studie stoel: Ruth A. Karron, MD, Center for Immunization Research, Johns Hopkins University School of Public Health
Publicaties en nuttige links
Algemene publicaties
- Madhi SA, Cutland C, Zhu Y, Hackell JG, Newman F, Blackburn N, Murphy BR, Belshe RB, Karron RA, Deatly AM, Gruber WC, Bernstein DI, Wright PF. Transmissibility, infectivity and immunogenicity of a live human parainfluenza type 3 virus vaccine (HPIV3cp45) among susceptible infants and toddlers. Vaccine. 2006 Mar 20;24(13):2432-9. doi: 10.1016/j.vaccine.2005.12.002. Epub 2005 Dec 20.
- Skiadopoulos MH, Surman SR, Riggs JM, Orvell C, Collins PL, Murphy BR. Evaluation of the replication and immunogenicity of recombinant human parainfluenza virus type 3 vectors expressing up to three foreign glycoproteins. Virology. 2002 May 25;297(1):136-52. doi: 10.1006/viro.2002.1415.
Studie record data
Bestudeer belangrijke data
Studie start
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Schatting)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- CIR 255
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Virusziekten
-
U.S. Army Medical Research and Development CommandVoltooid
-
ModernaTX, Inc.WervingRespiratoir sincytieel virusCanada, Verenigd Koninkrijk, Japan, Verenigde Staten, Chili, Denemarken, Panama, Zuid-Afrika
-
Merck Sharp & Dohme LLCVoltooidRespiratoir sincytieel virusVerenigd Koninkrijk
-
Dalhousie UniversityImmunoVaccine Technologies, Inc. (IMV Inc.)VoltooidRespiratoir sincytieel virusCanada
-
ModernaTX, Inc.Actief, niet wervend
-
ModernaTX, Inc.WervingRespiratoir sincytieel virusCanada, Verenigde Staten, Verenigd Koninkrijk, Puerto Rico
-
ModernaTX, Inc.Actief, niet wervendRespiratoir sincytieel virusVerenigde Staten, Panama
-
ModernaTX, Inc.Actief, niet wervendRespiratoir sincytieel virusVerenigde Staten, Spanje, Taiwan, Korea, republiek van, Singapore, Canada, België, Finland, Japan, Verenigd Koninkrijk, Chili, Nieuw-Zeeland, Zuid-Afrika, Australië, Puerto Rico, Argentinië, Costa Rica, Polen, Bangladesh, Colombia en meer
-
Leiden University Medical CenterUMC Utrecht; Erasmus Medical Center; Leiden University; Netherlands Institute of...Voltooid
-
National Institute of Allergy and Infectious Diseases...Actief, niet wervendRespiratoir syncytieel virus (RSV)Verenigde Staten
Klinische onderzoeken op rHPIV3cp45
-
National Institute of Allergy and Infectious Diseases...Johns Hopkins Bloomberg School of Public HealthVoltooidVirusziekten | Paramyxoviridae-infectiesVerenigde Staten
-
National Institute of Allergy and Infectious Diseases...VoltooidPara-influenzavirus 3, mensVerenigde Staten, Puerto Rico